Vigil Neuroscience, Inc. (NASDAQ:VIGL – Get Free Report) CEO Ivana Magovcevic-Liebisch acquired 4,000 shares of the business’s stock in a transaction on Monday, November 20th. The shares were purchased at an average price of $3.75 per share, for a total transaction of $15,000.00. Following the transaction, the chief executive officer now directly owns 207,687 shares of the company’s stock, valued at $778,826.25. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.
Vigil Neuroscience Price Performance
Vigil Neuroscience stock opened at $3.65 on Tuesday. The stock has a market cap of $130.95 million, a price-to-earnings ratio of -1.79 and a beta of 2.78. The firm has a 50-day moving average of $6.32 and a two-hundred day moving average of $7.57. Vigil Neuroscience, Inc. has a 1 year low of $3.60 and a 1 year high of $13.55.
Wall Street Analyst Weigh In
A number of research firms recently commented on VIGL. HC Wainwright reaffirmed a “buy” rating and set a $24.00 price target on shares of Vigil Neuroscience in a research note on Thursday, September 14th. Mizuho dropped their target price on Vigil Neuroscience from $15.00 to $13.00 in a research report on Thursday, August 10th. Wedbush reiterated an “outperform” rating and issued a $23.00 price target on shares of Vigil Neuroscience in a report on Friday. Finally, JMP Securities assumed coverage on Vigil Neuroscience in a research note on Wednesday, October 18th. They set an “outperform” rating and a $23.00 price target for the company. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $19.20.
Institutional Trading of Vigil Neuroscience
Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of Montreal Can purchased a new position in Vigil Neuroscience during the 2nd quarter worth $728,000. Bank of America Corp DE bought a new position in shares of Vigil Neuroscience during the 4th quarter worth $124,000. JPMorgan Chase & Co. purchased a new position in shares of Vigil Neuroscience during the second quarter valued at $120,000. Morgan Stanley raised its holdings in shares of Vigil Neuroscience by 6,893.8% in the fourth quarter. Morgan Stanley now owns 9,092 shares of the company’s stock valued at $114,000 after acquiring an additional 8,962 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Vigil Neuroscience by 87.1% during the 2nd quarter. Renaissance Technologies LLC now owns 37,488 shares of the company’s stock worth $97,000 after acquiring an additional 17,447 shares in the last quarter. Institutional investors own 71.80% of the company’s stock.
About Vigil Neuroscience
Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
- Five stocks we like better than Vigil Neuroscience
- 3 Healthcare Dividend Stocks to Buy
- The most upgraded stocks in November have two things in common
- Financial Services Stocks Investing
- Monday.com rocked earnings like it’s the weekend
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Plan to own one retailer? Make it this one
Receive News & Ratings for Vigil Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vigil Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.